A Cucumber Mosaic Virus Based Expression System for

the Production of Porcine Circovirus Specific Vaccines by Gellért, Ákos et al.
A Cucumber Mosaic Virus Based Expression System for
the Production of Porcine Circovirus Specific Vaccines
A´kos Gelle´rt1, Katalin Sala´nki2, Kata Tomba´cz3, Tama´s Tuboly3, Ervin Bala´zs1*
1Department of Applied Genomics, Agricultural Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, H-2462 Martonva´sa´r, Brunszvik, Hungary,
2Agricultural Biotechnology Center, H-2100 Go¨do¨llo˝, Szent-Gyo¨rgyi Albert, Hungary, 3Department of Microbiology and Infectious Diseases, Szent Istva´n University
Faculty of Veterinary Science, Budapest, Hungary
Abstract
Potential porcine circovirus type 2 (PCV2) capsid protein epitopes, suitable for expression on the surface of cucumber
mosaic virus (CMV) particles were determined by a thorough analysis of the predicted PCV capsid protein structure. The ab
initio protein structure prediction was carried out with fold recognition and threading methods. The putative PCV epitopes
were selected on the basis of PCV virion models and integrated into the plant virus coat protein, after amino acid position
131. The recombinants were tested for infectivity and stability on different Nicotiana species and stable recombinant virus
particles were purified. The particles were tested for their ability to bind to PCV induced porcine antibodies and used for
specific antibody induction in mice and pigs. The results showed that PCV epitopes expressed on the CMV surface were
recognized by the porcine antibodies and they were also able to induce PCV specific antibody response. Challenge
experiment with PCV2 carried out in immunized pigs showed partial protection against the infection. Based on these results
it was concluded that specific antiviral vaccine production for the given pathogen was feasible, offering an inexpensive way
for the mass production of such vaccines.
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Introduction
Vaccines have been revolutionary for the prevention of
infectious diseases especially in case of virus induced clinical
conditions. Beside the continued development of the inactivated or
live attenuated vaccines, major efforts are invested in subunit
vaccines [1] for either mucosal or parenteral delivery to overcome
shortages of the traditional types. Subunit vaccine refers to
pathogen-derived antigens, sometimes limited to one or more
immunogenic domains of a protein, which cannot cause disease
but can, activate the host immune response system against the
pathogen. A special area of subunit vaccine production is offered
by the use of plants, either as transgenic plants or as natural media
for the propagation of recombinant plant viruses expressing
a desired gene of an animal or human pathogen. Such vaccines,
also as edible ones, have been at the focus of research since the first
report of transgenic tobacco plants expressing hepatitis B surface
antigen (HBsAg) [2], proving that HBsAg can stimulate mucosal
immune responses via the oral route [3]. Using similar approaches
a number of important veterinary pathogens were targeted and the
vaccines showed promising results after oral or parenteral
application [4–7]. Plant derived antigens offer several advantages
over traditional vaccines, including stability, increased safety, rapid
and massive production, cost effectiveness and especially in case of
plant seeds long term storage and long distance shipment at
variable temperatures [8–11].
The pioneering work of Lomonossoff’s group on a versatile
plant virus expression system based on the icosahedral cowpea
mosaic virus (CPMV) gave a burst to the development of
alternative expression systems from plant RNA viruses [12–14].
One of the first such experiments used CPMV after the crystal
structure of the virus particle had been resolved, allowing for the
precise insertion of the epitopes into the coat proteins [15–17].
The number of similar expression systems using plant viruses is
constantly increasing [18]. Recently cucumber mosaic virus
(CMV) was considered as a potential vector for expressing foreign
epitopes [19,20]. Furthermore, CMV is a promising candidate as
an oral vaccine, since it has an extremely wide host range, and
accumulates in substantial amount in different parts of the plants,
like leaves, fruits, tubers and roots.
A target of plant virus based vaccine development is
suggested in the present study, namely against porcine circovirus
(PCV) infections. PCV is one of the smallest known animal
viruses; it belongs to the Circovirus genus of the Circoviridae family.
It is non-enveloped with a single-stranded circular DNA
genome surrounded by a capsid built of the only structural
protein of the virus (the capsid protein) that is also the main
target of antiviral immune response [21–23]. Two species of
PCV have been identified so far, PCV1 [24] originally isolated
as a cell line contaminant and PCV2 that is strongly immune
suppressive and is responsible for a number of clinico-
pathological conditions, referred to as PCV associated diseases
(PCVD) [25]. PCV2 is present worldwide causing major
economic losses in the pig industry. The control of the infection
and PCVDs is crucial and traditional inactivated or subunit
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vaccines using baculovirus expression systems had been de-
veloped and commercialized. The efficacy of the available
vaccines, based on the average daily weight gain and on the
mortality rate in vaccinated herds is limited, but with beneficial
effect on both [26].
The detailed studies of the functions of important loops on the
coat protein subunits present on the surface of cucumoviruses [27–
31] initiated the current study to produce CMV expressing an
epitope of PCV2 (Fig. 1) that is important in the induction of
protective immunity against PCVDs.
Materials and Methods
Ethics Statement
The animal experiments were carried out in accordance with
the Guidelines for Animal Experiments of the Szent Istva´n
University and with EU Directive 2010/63/EU. The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the Szent Istva´n University and the Central Agricultural Office
(Directorate of Animal Health and Animal Welfare, Budapest,
Hungary, Permit Number: 22.1/1020/3/2010). The animals were
Figure 1. Molecular surface representations of the CMV virion. The whole molecular surface is colored in gray (A). External coat protein loops
are colored as follows (B): loop 1 (76–83 aa) is green, loop 2 (113–118 aa) is red, loop 3 (129–136 aa) is blue, loop 4 (156–163 aa) is magenta and loop
5 (193–199 aa) is yellow. The PCV2 epitope insertion points are indicated in panel C. Ser 131 and 132 are represented as orange beads. Panel D is the
superposition of B on C.
doi:10.1371/journal.pone.0052688.g001
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carefully monitored for any sign of distress, and all efforts were
made to minimize animal suffering. Both mice and pigs remained
symptomless throughout the study.
Prediction of the PCV2 Capsid Protein Structure and
Molecular Graphics
The PCV2 capsid protein (CP) structure was generated with I-
TASSER [32,33]. The model was built using the PCV2 CP
sequence (NCBI/GenBank accession number: AAC35310). The
following experimentally determined templates were used to
thread the PCV2 CP structure: PDB ID codes: 2EIG (Lotus
tetragonolobus seed lectin), 1V6I (Peanut lectin), 1C8N (Tobacco
necrosis virus CP), 1NT0 (CUB1-EGF-CUB2 region of mannose-
binding protein), 1NG0 (Cocksfoot mottle virus CP), 1JOD
(pituitary adenylatecyclase-activating polypeptide), 1E4B (L-fucu-
lose-1-phosphate aldolase). A PCV2 CP pentamer was created
with Symmdock [34] for graphical epitope visualization. The
model structures were refined with the Schro¨dinger molecular
modeling software package (Schro¨dinger Suite) to eliminate the
steric conflicts between the protein side chain atoms. Molecular
graphics were created with VMD version 1.9 [35]. The virion
models were created with the Oligomer Generator application of
VIPERdb (available at http://viperdb.scripps.edu/
oligomer_multi.php). Prior to virion model generations the
asymmetric units were constructed with Schro¨dinger Suite using
the coordinates of subunit A, B and C of CMV CP.
Plasmid Constructs
R-CMV and the infectious transcripts (pR1, pR2, pR3) derived
from this strain have been described previously [36]. The
recombinant RNA 3 clones were generated by polymerase chain
reaction (PCR) based mutagenesis of pR3. Oligonucleotide
primers to insert the PCV derived regions were designed with
the SilMut software package [37]. Oligonucleotides for pR3/131-
PCV126-145 contained SnaBI restriction endonuclease (RE) site,
and BamHI for pR3/131-PCV224-233. The oligonucleotides were
as follows:
R3/131PCV126-145 forward: 59-GGG TAC GTA CGA CCC
ATA TGT AAA CTA CTC ATC CGA TCT TTC CGT CG-39,
R3/131PCV126-145 reverse: 59-GGG TAC GTA AGT GCT
GTT GCT TTA GTG ACA AAG TTA TCG TCT CCT GAA
AGG TA CTT TCC GAA CTG T-39, R3/131PCV224-233 forward:
59-GGG GGA TCC ACC ACT AAA ACC ATC CGA TCT TTC
CGT CGC CG-39, R3/131PCV224-233 reverse: 59-GGG GGA
TCC TTA AGT TGA ATC CTG AAG GTA CTT TCC GAA CTG
TAA CCC-39. (The RE recognition sequences are underlined, the
inserted PCV derived regions are bold and the sequences
complementary with the viral sequences are italics.) The PCR
reactions were carried out with Pfu polymerase (Fermentas) to
minimize the chance of non-intentionally introduced mutations.
After the PCR reaction the product containing the full length
clone terminated with the PCV derived epitope sequence was
digested with the appropriate restriction enzymes (SnaBI or
BamHI) and the plasmid was recircularized. The nucleotide
sequence of the recombinant clones was confirmed by automated
dideoxy sequencing. Schematic graphical illustration of the
plasmid constructions were previously published by Nuzzaci et al.
[19] and Vitti et al. [20].
Plant Inoculation
Plants were inoculated at the three-leaf (Nicotiana tabacum L. cv.
Xanthi) or six-leaf (N. clevelandii) stage with purified virions or with
in vitro transcripts. For plant inoculation 20 mg/ml virion was used
in 0.03 M Na2HPO4, (pH 8.7). The constructs were transcribed
in vitro with T7 RNA polymerase (Fermentas). For inoculation,
2 mg of each of the RNA 1, 2 and 3 transcripts were used per plant
in 50 ml 50 mM Na2HPO4, pH 8.6. The plants were kept in
environmentally controlled growth chambers with a cycle of 14 h
of light (22uC) and 10 h of dark (18uC). Chimeric viruses were
tested under confinement conditions in accordance with national
regulations. The average virion production rate was 70 mg per
100 g of leaf material.
Analysis of Plants
Total RNAs were extracted from 200 mg systemically infected
leaves 21 days after inoculation [38,39]. Approximately 100 ng
total RNA was denatured with formaldehyde and formamide
(Sigma-Aldrich), electrophoresed in formaldehyde-containing aga-
rose gels and blotted onto nylon membranes [40]. Northern blot
hybridization analysis was performed with random-primed 32P-
labelled DNA fragments specific for the CMV RNA3 sequence as
described previously [36].
Virions were purified according to the method described by Lot
et al. [41]. RNA was extracted from virions with phenol and SDS.
RT-PCR analysis was carried out with the CMV 39 end primer
(59-GGCTGCAGTGGTCTCCTTATGGAGAACCTGTGG-
39) and a forward primer located at nucleotide position 1273–1292
of RNA3 (59-CGTCGTCGCCCGCGTAGAGG-39). The nucle-
otide sequence of the amplified fragment was determined.
Detection of PCV2 Cap Epitope by ELISA
The presence of the PCV2 epitope in the recombinant CMV
particles was detected by an indirect enzyme linked immune
sorbent assay (ELISA). Recombinant or wild type virus particles
were released, concentrated and purified from infected plants by
standard methods [41]. The presence of the epitope was tested
by the use of a PCV2 specific hyperimmune polyclonal swine
antiserum previously produced by a series of PCV2 vaccinations
and subsequent booster infection [42]. PCV2 negative pig
serum was used as negative control. The viral antigens were
dissolved by 1% sodium laurylsarcosinate (Sigma-Aldrich) and
diluted to a concentration of 1 mg/ml in phosphate buffered
saline (PBS), plated in twofold serial dilutions, 100 ml/well, into
ELISA plates. The plates were incubated overnight in a humid
chamber at 4uC. Tenfold dilutions of the hyper immune serum
were applied in a checkerboard fashion in a standard ELISA
protocol, using horseradish peroxidase labeled anti-pig IgG
conjugate (Sigma-Aldrich) to detect bound antibodies. Incuba-
tions were performed for one hour at room temperature, with 3
washes between each step, using 150 ml of washing buffer (PBS,
0.05% Tween 20) for each well. Wild type CMV served as
negative antigen control.
Immunization of Mice
Both recombinant and wild type CMV preparations were used
for the immunization of mice in order to test the immunogenicity
of the PCV2 epitopes. Fifteen female SPF mice (CRL: NMRI BR,
Charles River, USA) of 8 weeks of age were divided into 3 groups.
Group 1 received the wild type virus, group 2 a recombinant
CMV carrying the PCV2_224-233aa capsid protein sequence and
group 3 was mock immunized with PBS. The vaccines were
applied intraperitoneally as mixtures of 100 ml (10 mg) of the
antigen (or PBS) mixed with equal volume of incomplete Freund’s
adjuvant (Sigma-Aldrich). Mice were vaccinated twice with a 2
weeks interval and exterminated 30 days after the first injection.
Blood was collected and immune sera separated.
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PCV2 Challenge of Immunized Pigs
Thirteen conventional PCV2 free (confirmed by PCR and
antibody detecting IF test) piglets were weaned at 2 weeks of age
and divided into 3 groups. The experiments started at the age of 4
weeks. Five piglets (group 1) were injected intramuscularly with
2 mg of the recombinant CMV, mixed with incomplete Freund’s
adjuvant, in a total volume of 2 ml. Five piglets (group 2) were
vaccinated with inactivated PCV2 vaccine (Circovac, Merial).
Immunizations were repeated after 10 days. The remaining 3
animals were mock immunized (group 3). Ten days after the
second immunization all of the piglets were challenged with
virulent live PCV2 (strain R15, kindly provided by dr. A. Csa´gola,
Szent Istva´n University, Budapest, Hungary), administered both
orally (56103 TCID50) and intraperitoneally (2610
3 TCID50).
Piglets were examined for clinical sings of PCVDs (diarrhea,
respiratory distress, skin lesions, general condition) and blood
samples were collected before the first vaccination and once a week
during the entire study for PCV2 antibody testing. The piglets
were euthanized following general anesthesia on the 23rd day after
challenge [43]. Post mortem examinations were carried out; organ
samples (heart, lung, liver, spleen, kidney, tonsil, mediastinal and
inguinal lymph nodes) were collected from each animal and stored
at 220uC until processing.
Immune Fluorescence Test
Sera from the immunized mice and pigs were analyzed for the
presence of PCV2 specific antibodies in an indirect immune
fluorescence assay, according to standard protocols. Briefly,
Spodoptera frugiperda (Sf) 9 insect cells in 96 well tissue culture plates
were infected in parallel rows with a recombinant baculovirus
producing PCV2 capsid protein and with wild type baculovirus
(Autographa californica nuclear polyhedrosis virus), both with
a multiplicity of infection of 1 per cell, or were left uninfected.
The recombinant baculovirus produced with the BacPAKTM
Expression System (Clontech) was kindly provided by dr. A.
Csa´gola. Cell cultures were fixed after 2 days of incubation with
200 ml of an ethanol:acetone 1:1 mixture for each well. After 10
minutes the fixed cells were air dried and used for the indirect
immune fluorescence tests. The sera collected from mice and pigs
were applied in twofold dilutions starting with 1:5, the results were
evaluated after the addition of mouse or pig specific FITC
conjugated antibodies (Sigma-Aldrich) in a fluorescent microscope.
Detection of PCV2 DNA in Infected Pigs
Samples were homogenized using TissueLyser II (Quiagen) and
viral DNA was extracted using the InnuPREP Virus DNA/RNA
Kit (Analytik Jena AG) according to the manufacturer’s instruc-
tions. Quantitative real-time polymerase chain reaction (qPCR)
was used to detect PCV2 DNA. Primers (KCV-F: 59- AAG-
TAGCGGGAGTGGTAGGA-39 and KCV-R: 59-
GGGCTCCAGTGCTGTTATTC-39) and the TaqMan probe
(KCV-P: 59FAM- TCCCGCCATACCATAACCCAGC-
39BHQ1) were designed for the PCV2-R15 capsid gene sequence
with the online tool (https://www.genscript.com/ssl-bin/app/
primer). To determine copy numbers, a serial dilution of
pET6xHN plasmid (Clontech) with the PCV2 capsid gene insert
was used as internal standard. The sensitivity of the test was
between 10 to 100 copies/reaction. Duplicate PCR reactions were
performed in 50 ml reactions, each containing 36.3 ml water, 5 ml
DreamTaq buffer (Fermentas), 1 ml (0.5 mM) MgCl2 (Fermentas),
1 ml (0.2 mM) dNTP mixture (Fermentas), 0.5 ml of each primer
and the probe (0.1 mM), 0.2 ml (1 unit) polymerase (DreamTaq,
Fermentas) and 5 ml sample DNA. Reactions were performed in
the Mastercycler Realplex thermocycler (Eppendorf) as follows:
94uC for 2 minutes, 30 cycles of 94uC, 30 s, 60uC 30 s and 72uC,
45 s, followed by cooling to 25uC.
Results
Epitope Prediction on the PCV2 CP Model
A PCV2 CP pentamer model was created from the predicted
PCV2 CP so that the N-terminal a-helices form parallel bundle
along a fivefold axis. This pentamer mimicked a partial external
and internal surface of the PCV2 virion (Fig. 2, C and D). Five
outer loop regions were identified on the basis of visual observation
of the PCV2 pentamer three-dimensional model as potential
epitopes during immune response. The predicted PCV2 epitope
sequences, indicated by their nucleotide positions and length in
amino acids (in parenthesis) were as follows: PCV2_37-43(7):
RWRRKNG, PCV2_90-96(7): SIPFEYY, PCV2_126-145(20):
DDNFVTKATALTYDPYVNYS, PCV2_169-186(18): STI-
DYFQPNNKRNQLWLR, PCV2_224-233(10): FNLKDPPLKP.
On the basis of spatial distribution it was predicted that the
PCV2_224-233 epitope bundle may trigger a major immune
response as it is localized at the centre of the CP pentamers (Fig. 2
C and D). The 20 aa long PCV2_126-145 peptide fragment is the
longest predicted epitope therefore it was selected to test its
insertion properties. Insertion of the epitope to the 131aa position
of CMV CP results PCV2 epitope trimer bundles in the centre of
the CMV CP trimers of the virion surface (Fig. 2 A and B, Fig. 3).
The X-ray structure of the PCV2 virion was published in August
2011 by Khayat et al. [44]. The experimentally determined PCV2
structure partially confirmed the relevance of our previously
predicted model. In the above mentioned study it was confirmed
that the C-terminal tail of the capsid protein indeed localized to
the PCV2 virion surface (Fig. 4).
Expression of PCV2 CP Derived Epitope on CMV Surface
Three stable epitope insertion points were detected in CMV to
date [19,20]. The built-in epitopes at these points did not block the
propagation of CMV and the long-distance movement in plants.
Two of them are displayed on the external surface of the virion
while the third protrudes towards the inside of the virion (Fig. 3).
There is an electrostatic limitation to express epitopes facing the
inside of the virion as only the expression of epitopes with positive
charge, that do not interfere with the RNA-binding of the inner
surface of the CMV capsid can successfully be attempted.
Two out of the five predicted epitopes were inserted after 131 aa
position of the CMV CP. Nicotiana clevelandii Gray and N. tabacum
L. cv. Xanthi plants were inoculated with the recombinant and
control in vitro transcripts in the presence of R-CMV RNA 1 and 2
transcripts. Systemic symptoms were observed 6–8 days after the
inoculation in the case of the control infection (R-CMV), after 8–
10 days in the case of the pR3/131-PCV224-233 construct, but
symptoms never were observed in the case of the pR3/131-
PCV126-145 construct. The Northern analysis confirmed the
visual observation (Fig. 5).
In the upper, not inoculated leaves the recombinant virus was
detected in the case of the pR3/131-PCV224-233 construct, but
not in the case of the pR3/131-PCV126-145 14 days after the
inoculation. The virus was further propagated on N. clevelandii
Gray plants and purified ten days after the inoculation. The yield
of the virus purification in the case of pR3/131-PCV224-233 was
similar to the purification yield of the wild type R-CMV. The
purified virus RNA was analyzed by RT-PCR and nucleotide
sequence determination. The integrated epitope sequence proved
to be stable after one month propagation in test plants. Electron
microscopic studies proved the identical size and shape of the
CMV Based Expression System for New PCV2 Vaccines
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recombinant (R3/131-PCV224-233) and the R-CMV virus
particles (data not shown). Nevertheless after 5–6 months
propagation and serial passages on the Nicotiana clevelandii, Nicotiana
benthamiana or Nicotiana tabacum cv. Xanthi plants the complete
deletion of the PCV2 epitope was observed. During long term
maintenance in a few cases residue 131 of the CMV coat protein
mutated to Pro or Ser after the insert deletion. Optimization of
propagation time, appropriate plant species selection and effective
growth condition development will be required to further increase
the stability of the epitope.
Antigenicity and Immunogenicity of the Recombinant
PCV2 Epitopes
The ELISA test showed that the PCV2 epitope was present in
the CMV capsid, as the polyclonal PCV2 specific pig antibodies
reacted with the recombinant construct but not with the wild type
virus. The titer (1:10000) of the pig serum measured with the
original PCV2 virus antigen was lower (1:100) when using the
recombinant virus. The immune sera collected from mice
vaccinated with the recombinant CMV construct induced PCV2
specific antibodies, as indicated by the immune fluorescence test
(Fig. 6). The titer of the antibodies was between 1:80 and 1:320.
PCV2 specific antibodies in pigs appeared after the second
immunization in group 1, after the first immunization in group 2
and only after challenge in group 3 (Fig. 7). No PCV2 DNA was
detected in group 2 and the virus was demonstrated in only 2
animals after challenge in group 1. The DNA copy numbers
measured by qPCR varied between 103 (in lungs of one piglet) and
105 (mediastinal lymph node of another piglet) in group 3. In
group 1 both the lungs and the mediastinal lymph nodes of one
piglet contained PCV2 DNA, but the rest of the organs were free
Figure 2. CMV and PCV epitopes on the virion surface. Spatial localization of the epitopes on the modified CMV CP trimer (A, B) and on the
predicted PCV2 pentamer surface (C, D). The epitope (PCV2_224-233) was inserted after the 131 aa position. The CMV subunits A, B and C are cyan,
pink and gold, respectively. The epitope is illustrated in licorice representation. The basic amino acids are blue, acidic amino acids are red, the non-
polar amino acids are gray and the polar amino acids are colored in green. Plan view of the external surface of the predicted PCV2 CP pentamer (C)
and the side view of the pentamer showing the outer surface and the inner surface part (D). External PCV2 capsid protein epitope colors: PCV2_37-43
is ice cube, PCV2_90-96 is mauve, PCV2_126-145 is cyan, PCV2_169-186 is pink and PCV2_224-233 is colored with the above used color schemes.
doi:10.1371/journal.pone.0052688.g002
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Figure 3. Visualization of epitope insertion points in CMV. Localization of stable epitope insertion sites G83/S84 (blue), G131/S132 (red) and
D176/I177 (green) in CMV. The first two sites are on the external surface of the virion while the third is located towards the inside of the virion (A). The
CMV subunits A, B and C are cyan, pink and orange, respectively. The symmetrical distribution of the inserted epitope (red) is visible on the Van der
Waals representation of the modified CMV virion surface (B).
doi:10.1371/journal.pone.0052688.g003
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of the virus. PCV2 was also detected in another piglet of the same
group but the virus in this animal was only present in the lungs.
Clinical and macroscopic post mortem examinations did not
reveal any sign of clinical manifestation of the infection. The
presence of subclinical disease (decreased feed conversion, effects
on co-infections and vaccinations) could not be determined under
these experimental conditions.
Discussion
There is a growing need for the development of safe and
efficient vaccines to prevent and control human and animal
diseases, especially those of viral origin. With the development of
molecular biology based technologies a number of new approaches
are already being utilized in vaccine design and production. Some
of them, like the baculovirus expression system have proven most
efficient, but the necessity of vaccines able to induce protective
immunity combined with cost effective production still remains.
Plant based antigen synthesis offers the possibility of mass
production of relatively inexpensive oral or parenteral vaccines.
Safe production of such antigens without the risk of environmental
contamination is easily provided by the use of bioreactors.
Furthermore, the infectious clones utilized in this study offer
a flexible, simple and rapid system for the introduction of new
epitopes into recombinant particles.
Porcine circovirus was chosen as the pathogenic animal model
virus for the present study. PCV infections are present worldwide
and cause major losses in the pig industry. The virus is responsible
for a variety of diseases (PCVDs) [45] but also it is well known for
its immune suppressive nature. PCV2 infected pigs are more
susceptible to secondary infections and do not respond to
vaccinations as expected.
Since the successful results obtained with heterologous proteins
produced in plants, either via foreign gene integration into the
plant genome or expressed transiently by a replicating recombi-
nant virus, several veterinary vaccine candidates have been
produced [8] some of them are under clinical trials. Using
sophisticated computer modeling methods for generating a virus
capsid protein structure of the PCV2 capsid, predicted epitopes
were suggested, designed and sequences representing these protein
segments were inserted into the cucumber mosaic virus capsid
protein. There are several experimentally described PCV2
epitopes which were mainly determined by immunological epitope
mapping methods [21–23,46]. Some of the predicted epitope
sequences overlapped with the experimentally mapped epitopes
but the lengths were not equal. This difference is due to the
determination method of the predicted PCV2 epitopes because
our determination has been based on three-dimensional modeling
of PCV2 CP pentamer which represents a part of the PCV2 virion
surface while the monomer PCV2 CP or its peptide fragments
(PEPSCAN) were used in the epitope mapping experiments. Based
on structure-based epitope prediction methods we were able to
select a potential PCV2 epitope which can induce an efficient
immune response.
Our earlier studies [31] determined several loops on the virion
surface of CMV that were essential for the formation of infectious
Figure 4. X-ray structure of the PCV2 virion (PDB ID code: 3R0R). The last seven residues are not present in the X-ray structure but it is well
visible that the C-terminal tail (red) of the PCV2 capsid protein is located at the edge of the CP pentamer.
doi:10.1371/journal.pone.0052688.g004
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virus particles. Loops were also identified which can be changed
without loss of virus stability and infectivity. During the present
study the virion models were created utilizing the Oligomer
Generator application with the constructed asymmetric units using
A, B and C coat proteins of the plant virus. Three suitable
insertion sites were determined by Nuzzaci et al. [19] and Vitti
et al. [20] on the CMV CP. The insertion points are summarized
in Figure 3. In terms of immunization the following conclusions
can be drawn based on the conformational features of the insertion
positions: 1- Insertion point 83–84 is located at the end of the bB-
bC loop of the CMV CP. The built-in epitopes are expressed on
the surface of CMV virions and are located far apart. Thus,
production of antibodies might be induced by the assembled virion
or the monomeric capsid proteins. 2- Insertion point 131–132 is
located in the middle of the bE-aEF loop of the CMV CP. The
above mentioned conclusion is true for this insertion point as well
but this position has the advantage that the inserted epitopes form
a tripartite group in the middle of the CMV CP trimers (Fig. 2 A
and B). So these epitope bundles may allow the production of
antibodies more efficiently. 3- Insertion point 176–177 is located
in the middle of the bG-bH loop. In this case the inserted epitopes
are expressed on the inner surface of CMV virions therefore this
construction can only induce immune response after virion
disassembly.
In our study only the pR3/131-224-233 construct was infectious
on different test plants, but the pR3/131-126-145 constructs never
induced systemic infection. While in the first case a 10 aa long
fragment was integrated into the CMV CP, in the second case a 20
aa long region was introduced into the same position. Possibly
there is a size limit of the inserted sequence tolerated by the virus.
In the same position a 12 aa long Alzheimer disease derived
oligopeptide was tolerated, but a 15 aa long derivative was also
unstable even after one passage on Nicotiana tabacum L. cv. Xanthi
plants [20]. Probably above a certain size, depending also on the
secondary structure, the inserted peptide interferes with virus
replication and particle assembly.
The presence and proper appearance of the epitope derived
from PCV2 capsid on the CMV virion surface was verified by its
ability to bind to PCV2 induced antibodies and also by its ability
to induce such antibodies both in mice and pigs. Although the
antibodies were demonstrated in pigs, they only appeared after the
second dose of vaccine, indicating that either the amount of
injected antigen was too low for pig immunization or that the
single epitope of the PCV2 capsid is relatively less immunogenic
than the entire capsid protein. According to the qPCR results,
vaccination with the recombinant CMV decreased virus spread in
the challenged animals, although somewhat less efficiently than the
Figure 5. RNA detection. Northern blot analysis of accumulated viral
RNAs in systemically infected leaves of N. clevelandii Gray plants 14 days
after the inoculation. The hybridization probe was specific to RNA3 of
CMV. Ethidium bromide-stained rRNA from the same volume of each
sample is shown below each lane. Lane 1: mock inoculated, 2: R-CMV, 3:
pR3/131-PCV224-233, 4: pR3/131-PCV126-145.
doi:10.1371/journal.pone.0052688.g005
Figure 6. Detection of PCV2 specific antibodies. Indirect immune fluorescence test results of sera from mice immunized with recombinant (A)
or wild type (B) CMV, detected in PCV2 capsid expressing baculovirus infected cells. The pictures show the results obtained with 1:40 serum dilution
of both antibodies.
doi:10.1371/journal.pone.0052688.g006
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control vaccine. Effects of the vaccination on clinical or subclinical
manifestations of PCVDs could not be evaluated in this
experiment, because the reproduction of the disease is hard to
achieve with PCV2 inoculation only [45], since PCV2-related
pathomechanisms are activated by modulation of the immune
system or infections by other pathogens [47]. Based on the
antibody and the challenge results it was concluded that PCV2
specific vaccines can be produced by CMV expression but further
experiments are needed to determine the most suitable vaccination
protocol, in terms of dosage, frequency and perhaps also the
adjuvant to be used.
According to these results the CMV vector proved suitable for
the accurate expression of the inserted PCV2 epitope. Experi-
ments will be needed both in mice and in pigs to determine if the
given or further constructs are able to induce not only a systemic
immunity following parenteral vaccination but also mucosal
immunity against PCVDs when fed to the animals.
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